Renovia Inc. is a startup organization that Marc Beer, Aegerion Pharmaceuticals’s former CEO co-founded. The organization will be going forward with various new products for disorders in the pelvic floor after its closing on Tuesday with a $32 million Series B round alongside $10 million in venture debt. The MedTech company which is located in Boston is creating several therapeutic and diagnostic products to fight pelvic floor disorders such as urinary incontinence. According to scholars, the urinary incontinence is affection over 250 million women across the world. The first product of Renovia received a FDA endorsement in April. A healthcare-focused investment company, the Lakewood Fund was the first to invest in Renovia, and it also joined the Series B round. Perceptive Advisors and Missouri-based Ascension Ventures found in New York was the leader of Series B round.
The funds from the event will be used in building and testing other four more diagnostic and therapeutic products as well as Leva device’s new generation. According to Beer, the CEO of Revonia, the company was happy that other leading investors in the healthcare sector were ready to support them. He went ahead to say that these were organizations that have the same vision as Renovia to better analyze, treat as well as enhance the lives of several women who are affected by pelvic floor disorders across the world. Bringing together their proprietary and innovative sensor technologies and create factors with a digital platform of healthcare will provide the company clients with valued data to update new options of treatment. Moreover, the clients will get informed concerning greater understanding and knowledge of pelvic floor disorders as well as the final lower long-term costs of healthcare.
Marc Beer also worked with OvaScience as its strategic consultant. OvaScience is a Waltham biotech firm that will be merging with Millendo Therapeutics. Marc Beer is the chairman, co-founder and CEO of Renovia Inc. Marc has been working in the commercialization and development areas of biotechnology, diagnostics, devices, and pharmaceuticals for over 25 years, an experience that is valuable to Renovia. Marc partnered with Ramon Iglesias and Yolanda Lorie in establishing Renovia in August 2016. The organization closed successfully a Series A financing with leading healthcare venture capital funds.
In October 2010, Marc managed to take the company public and its first product JUXTAPID got EDA approval in 2012 December. Marc Beer was also the board of directors’ founding chairman and Good Start Genetics, Inc.’s compensation committee chairman. Invitae acquired the company recently. Learn more : https://www.slideshare.net/MarcBeer